Gastroenteropancreatic neuroendocrine carcinoma (gep-nec)

Clinical trials for Gastroenteropancreatic neuroendocrine carcinoma (gep-nec) explained in plain language.

Never miss a new study

Get alerted when new Gastroenteropancreatic neuroendocrine carcinoma (gep-nec) trials appear

Sign up with your email to follow new studies for Gastroenteropancreatic neuroendocrine carcinoma (gep-nec), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New antibody drug targets Hard-to-Treat neuroendocrine cancers

Disease control Recruiting now

This study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…

Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA (GEP-NEC)

Phase 1/2 • Sponsor: Phanes Therapeutics • Aim: Disease control

Last updated Jul 17, 2026 00:00 UTC

Gastroenteropancreatic neuroendocrine carcinoma (gep-nec)

Get alerted when new Gastroenteropancreatic neuroendocrine carcinoma (gep-nec) trials appear

New antibody drug targets Hard-to-Treat neuroendocrine cancers